My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

36.53 -1.90 (-4.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,505,548
Open 38.48
Bid (Size) 36.50 (10)
Ask (Size) 38.90 (1)
Prev. Close 38.43
Today's Range 36.45 - 38.48
52wk Range 26.20 - 63.50
Shares Outstanding 56,367,802
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
From Apogee Therapeutics
Via GlobeNewswire

Performance

YTD
-22.5%
-22.5%
1 Month
+0.5%
+0.5%
3 Month
-11.7%
-11.7%
6 Month
-10.6%
-10.6%
1 Year
-37.5%
-37.5%

More News

Read More
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Gold Falls 1%; ProKidney Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Dips 1%; Mustang Bio Shares Spike Higher
Via Benzinga
Topics Stocks
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
Via Investor's Business Daily
What's going on in today's pre-market session
Via Chartmill
Top 2 Health Care Stocks That May Plunge This Month
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial
Via Benzinga
Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
From Apogee Therapeutics
Via GlobeNewswire
Why Is Apogee Therapeutics Stock Trading Higher On Monday?
Via Benzinga
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
From Apogee Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
Via Benzinga
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
From Apogee Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Apogee Therapeutics, Inc. - Common Stock publicly traded?
Yes, Apogee Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Apogee Therapeutics, Inc. - Common Stock trade on?
Apogee Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Apogee Therapeutics, Inc. - Common Stock?
The ticker symbol for Apogee Therapeutics, Inc. - Common Stock is APGE on the Nasdaq Stock Market
What is the current price of Apogee Therapeutics, Inc. - Common Stock?
The current price of Apogee Therapeutics, Inc. - Common Stock is 36.53
When was Apogee Therapeutics, Inc. - Common Stock last traded?
The last trade of Apogee Therapeutics, Inc. - Common Stock was at 09/19/25 04:00 PM ET
What is the market capitalization of Apogee Therapeutics, Inc. - Common Stock?
The market capitalization of Apogee Therapeutics, Inc. - Common Stock is 2.06B
How many shares of Apogee Therapeutics, Inc. - Common Stock are outstanding?
Apogee Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.